Cited by 520Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerCancer Mechanisms and Therapy

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, Kanaga, Lane, David P.·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.151

Open this paper in CoChat — free account

Abstract

TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated gene across all cancer types. The presence of mutant p53 predisposes to cancer development, promotes the survival of cancer cells, and is associated with ineffective therapeutic responses and unfavourable prognoses. Despite these effects, no drug that abrogates the oncogenic functions of mutant p53 has yet been approved for the treatment of cancer. Current investigational therapeutic strategies are mostly aimed at restoring the wild-type activity of mutant p53, based on the assumption that all p53 mutants are functionally equal. Our increasing knowledge of mutant forms of p53, however, supports the antithetical hypothesis that not all p53 mutants have equivalent cellular effects; hence, a judicious approach to therapeutic targeting of mutant p53 is required. In this Review, we propose a categorization of the major classes of p53 mutants based on their functionality in tumour suppression and response to therapy. The emerging picture is that the mutations across TP53 form a 'rainbow of mutants', with varying degrees of functionality and different pathobiological consequences, necessitating the use of diverse therapeutic strategies to selectively target specific classes of mutation. The utility of this knowledge of TP53 mutations in developing selective therapeutic options, and in facilitating clinical decision-making is discussed.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.151

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Self-citation
p53 in health and disease
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351
Self-citation

Flagged first, then by citations

Show all 178 references

Sorted by citations

Items 101–200 of 520

Tumor cell-derived extracellular vesicles for breast cancer specific delivery of therapeutic P53
Jiao, Y., Tang, Y., Li, Y., Liu, C., He, J., Zhang, L., & Guan, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.020 · Cited by 46
Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead
Jauset, T., & Beaulieu, M.-È. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.03.014 · Cited by 45
A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
Miller, J. J., Gaiddon, C., & Storr, T. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00163e · Cited by 47
The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells
Klemke, L., Fehlau, C. F., Winkler, N., Toboll, F., Singh, S. K., Moll, U. M., & Schulz‐Heddergott, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642603 · Cited by 50
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
Fiorentini, C., Grisanti, S., Cosentini, D., Abate, A., Rossini, E., Berruti, A., & Sigala, S. (2019) · Journal of Oncology · doi:10.1155/2019/6072863 · Cited by 45
Extracellular Vesicles: Messengers of p53 in Tumor–Stroma Communication and Cancer Metastasis
Pavlakis, E., Neumann, M. M., & Stiewe, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249648 · Cited by 45
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Markov state models and NMR uncover an overlooked allosteric loop in p53
de Barros, E. P., Demir, Ö., Soto, J., Cocco, M. J., & Amaro, R. E. (2020) · Chemical Science · doi:10.1039/d0sc05053a · Cited by 45
Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
Roszkowska, K. A., Piecuch, A., Sady, M., Gajewski, Z., & Flis, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113287 · Cited by 48
p53-Dependent Anti-Proliferative and Pro-Apoptotic Effects of a Gold(I) N-Heterocyclic Carbene (NHC) Complex in Colorectal Cancer Cells
Dabiri, Y., el Maaty, M. A. A., Chan, H. Y., Wölker, J., Ott, I., Wölfl, S., & Cheng, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00438 · Cited by 44
Molecular diagnosis of nasopharyngeal carcinoma: Past and future
Hsu, C., Chang, Y., & Li, H. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100748 · Cited by 46
Cancer gene therapy mediated by RALA/plasmid DNA vectors: Nitrogen to phosphate groups ratio (N/P) as a tool for tunable transfection efficiency and apoptosis
Neves, A. R., Sousa, Â., Faria, R., Albuquerque, T., Queiroz, J. A., & Costa, D. R. B. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110610 · Cited by 40
A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics
Wang, H., Ding, Y., Chen, Y., Jiang, J., Chen, Y., Lu, J., Kong, M., Mo, F., Huang, Y., Zhao, W., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01201-9 · Cited by 41
Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts
Brojakowska, A., Kour, A., Thel, M. C., Park, E., Bisserier, M., Garikipati, V. N. S., Hadri, L., Mills, P. J., Walsh, K. X., & Goukassian, D. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03777-z · Cited by 39
p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act
Guo, Y., Tang, Y., Lu, G., & Gu, J. (2023) · Nutrients · doi:10.3390/nu15102259 · Cited by 40
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity
Kondo, T., Bourassa, F. X. P., Achar, S. R., DuSold, J., Céspedes, P. F., Ando, M., Dwivedi, A., Moraly, J., Chien, C. D., Majdoul, S., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.017 · Cited by 40
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf, J. P., Shallis, R. M., Gowda, L., Wei, W., Hager, K. M., Isufi, I., Kim, T. K., Pillai, M. M., Seropian, S., Podoltsev, N. A., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1759051 · Cited by 37
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
Synnott, N. C., Madden, S. F., Bykov, V. J. N., Crown, J., Wiman, K. G., & Duffy, M. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.009 · Cited by 35
Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression
Feng, R., Yin, Y., Wei, Y., Li, Y., Li, L., Zhu, R., Xiao, Y., Liu, Y., Zhao, Y., & Liu, Z. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216154 · Cited by 35
MAPK Signaling‐Mediated RFNG Phosphorylation and Nuclear Translocation Restrain Oxaliplatin‐Induced Apoptosis and Ferroptosis
Di, Y., Zhang, X., Wen, X., Qin, J., Ye, L., Wang, Y., Song, M. L., Wang, Z., & He, W. (2024) · Advanced Science · doi:10.1002/advs.202402795 · Cited by 35
Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach
Ma, Z., Zhou, M., Chen, H., Shen, Q., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02975 · Cited by 43
A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms
Celik, H., Krug, E., Zhang, C. R., Han, W., Issa, N., Koh, W. K., Bjeije, H., Kukhar, O., Allen, M., Li, T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1652 · Cited by 40
PHLPP1 counter-regulates STAT1-mediated inflammatory signaling
Cohen‐Katsenelson, K., Stender, J. D., Kawashima, A. T., Lordén, G., Uchiyama, S., Nizet, V., Glass, C. K., & Newton, A. C. (2019) · eLife · doi:10.7554/elife.48609 · Cited by 33
Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors
Zhang, K. X., Ip, C. K., Chung, S. K., Lei, K. K., Zhang, Y. Q., Liu, L., & Wong, V. K. W. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.002 · Cited by 34
Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review)
Li, M., Sun, D., Song, N., Chen, X., Zhang, X., Zheng, W., Yu, Y., & Han, C. (2023) · Oncology Reports · doi:10.3892/or.2023.8599 · Cited by 42
Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology
Li, Q., Li, G., Li, P., Wang, H., Fang, X., He, T., & Li, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101155 · Cited by 35
Colorectal Cancer: An Update on Treatment Options and Future Perspectives.
Florescu-Ţenea, R. M., Kamal, A. M., Mitruț, P., Mitruţ, R., Ilie, D. S., Nicolaescu, A. C., & Mogoantă, L. (2019) · PubMed Central · doi:10.12865/chsj.45.02.02 · Cited by 35
Iron metabolism in colorectal cancer
Huang, L., Li, W., Lu, Y., Ju, Q., & Ouyang, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098501 · Cited by 34
The potential role of miRNAs in the pathogenesis of testicular germ cell tumors - A Focus on signaling pathways interplay
Doghish, A. S., Moustafa, H. A. M., Elballal, M. S., Sallam, A.-A. M., El‐Dakroury, W. A., Mageed, S. S. A., Elesawy, A. E., Abdelmaksoud, N. M., Shahin, R. K., Midan, H. M., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154611 · Cited by 32
Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response
Bao, Y., Yang, F., Liu, B., Zhao, T., Xu, Z., Xiong, Y., Sun, S., Qu, L., & Wang, L. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0189-4 · Cited by 31
Immune landscape and a promising immune prognostic model associated with TP53 in early‐stage lung adenocarcinoma
Wu, C., Rao, X., & Lin, W. L. (2020) · Cancer Medicine · doi:10.1002/cam4.3655 · Cited by 32
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Salama, A. K. A. A., Trkulja, M. V., Casanova, E., & Uras, I. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315440 · Cited by 36
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity
Isermann, T., Sener, Ö. C., Stender, A., Klemke, L., Winkler, N., Neeße, A., Li, J., Wegwitz, F., Moll, U. M., & Schulz‐Heddergott, R. (2021) · Nature Communications · doi:10.1038/s41467-021-24064-1 · Cited by 31
Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review)
Wang, X., Zhang, N., Li, M., Hong, T., Meng, W., & Ouyang, T. (2023) · Oncology Letters · doi:10.3892/ol.2023.13709 · Cited by 33
The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding
Gomes, A. S., Trovão, F., Pinheiro, B., Freire, F., Gomes, S., Oliveira, C., Domingues, L., Romão, M. J., Saraiva, L., & Carvalho, A. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041184 · Cited by 31
Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
Timofeev, O. N., Klimovich, B., Schneikert, J., Wanzel, M., Pavlakis, E., Noll, J., Mutlu, S., Elmshäuser, S., Nist, A., Mernberger, M., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2019102096 · Cited by 31
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53
Loh, S. N. (2020) · Biomolecules · doi:10.3390/biom10020303 · Cited by 30
Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8
Zhang, Y., Huang, X., Wang, L., Cao, C., Zhang, H., Wei, P., Ding, H., Song, Y., Chen, Z., Qian, J., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120720 · Cited by 31
Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity
Mariuzza, R. A., Wu, D., & Pierce, B. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303304 · Cited by 30
Experimental Data-Mining Analyses Reveal New Roles of Low-Intensity Ultrasound in Differentiating Cell Death Regulatome in Cancer and Non-cancer Cells via Potential Modulation of Chromatin Long-Range Interactions
Wang, J., Lai, B., Nanayakkara, G., Yang, Q., Sun, Y., Lu, Y., Shao, Y., Yu, D., Yang, W. Y., Cueto, R., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00600 · Cited by 29
Enhancing Chemotherapy of p53‐Mutated Cancer through Ubiquitination‐Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe‐4 Nanoparticles
Qian, J., Zhang, W., Wei, P., Yao, G., Yi, T., Zhang, H., Ding, H., Huang, X., Wang, M., Song, Y., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202001994 · Cited by 29
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
Marcellino, B. K., Farnoud, N. R., Cassinat, B., Lü, M., Verger, E., McGovern, E. M., Patel, M. A., Medina-Martinez, J. S., Levine, M. F., Ossa, J. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002379 · Cited by 31
Venetoclax in adult acute myeloid leukemia
Hu, M., Li, W., Zhang, Y., Liang, C., Tan, J. E., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115820 · Cited by 29
Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease
Wang, Y., Sano, S., Ogawa, H., Horitani, K., Evans, M. A., Yura, Y., Miura‐Yura, E., Doviak, H., & Walsh, K. X. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab215 · Cited by 26
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 31
CDK9 inhibitors reactivate p53 by downregulating iASPP
Wu, J., Liang, Y., Tan, Y., Tang, Y., Song, H., Wang, Z., Li, Y., & Lu, M. M. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109508 · Cited by 28
Revisiting the Role of p53 in Prostate Cancer
Teroerde, M., Nientiedt, C., Duensing, A. U., Hohenfellner, M., Stenzinger, A., & Duensing, S. M. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.prostatecancer.p53.2021 · Cited by 29
Therapeutic Strategies to Activate p53
Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 28
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olaoba, O. T., Adelusi, T. I., Yang, M. J., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16101808 · Cited by 28
Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
Liu, Y., Xu, F., Wang, Y., Wu, Q., Wang, B., Yao, Y., Zhang, Y., Han‐Zhang, H., Ye, J., Zhang, L., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10625 · Cited by 26
TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
Graziano, F., Fischer, N. W., Bagaloni, I., Bartolomeo, M. D., Lonardi, S., Vincenzi, B., Perrone, G., Fornaro, L., Ongaro, E., Aprile, G., et al. (2020) · Cancers · doi:10.3390/cancers12082049 · Cited by 26
The Changes in the p53 Protein across the Animal Kingdom Point to Its Involvement in Longevity
Bartas, M., Brázda, V., Volná, A., Červeň, J., Pečínka, P., & Zawacka‐Pankau, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168512 · Cited by 29
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm
Lajmi, N., Alves-Vasconcelos, S., Tsiachristas, A., Haworth, A., Woods, K., Crichton, C., Noble, T., Salih, H., Várnai, K. A., Branford-White, H., et al. (2024) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2024.1 · Cited by 31
Targeting p53 in chronic lymphocytic leukemia
Moia, R., Boggione, P., Mahmoud, A. M., Kodipad, A. A., Adhinaveni, R., Sagiraju, S., Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1832465 · Cited by 25
An Updated View of the Roles of p53 in Embryonic Stem Cells
Ayaz, G., Yan, H., Malik, N., & Huang, J. L. (2022) · Stem Cells · doi:10.1093/stmcls/sxac051 · Cited by 26
Engineered a dual-targeting HA-TPP/A nanoparticle for combination therapy against KRAS-TP53 co-mutation in gastrointestinal cancers
Mei, Y., Qin, X., Yang, Z., Song, S., Liu, X., Wu, C., Qian, J., Huang, X., Zhang, Y., & He, W. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.003 · Cited by 27
p53 involvement in clonal hematopoiesis of indeterminate potential
Chen, S., & Liu, Y. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000509 · Cited by 26
Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma
Gleber‐Netto, F. O., Neskey, D. M., Costa, A. F., Kataria, P., Rao, X., Wang, J., Kowalski, L. P., Pickering, C. R., Dias‐Neto, E., & Myers, J. N. (2020) · Cancer · doi:10.1002/cncr.33101 · Cited by 24
p53-R273H promotes cancer cell migration via upregulation of neuraminidase-1
Lv, T., Lv, H., Fei, J., Xie, Y., Lian, D., Hu, J. Y., Tang, L., Shi, X., Wang, J., Zhang, S., et al. (2020) · Journal of Cancer · doi:10.7150/jca.44718 · Cited by 24
Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma
Otani, S., Date, Y., Ueno, T., Ito, T., Kajikawa, S., Omori, K., Taniuchi, I., Umeda, M., Komori, T., Toguchida, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02120-w · Cited by 25
TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Le, X., Molife, C., Leusch, M. S., Rizzo, M. T., Peterson, P. M., Caria, N., Chen, Y., González-Gugel, E., & Visseren‐Grul, C. (2022) · Cancers · doi:10.3390/cancers14246127 · Cited by 27
Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death
Choe, J. H., Kawase, T., Xu, A., Guzman, A., Obradović, A., Low-Calle, A. M., Alaghebandan, B., Raghavan, A., Long, K., Hwang, P. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0882 · Cited by 25
p53 as Exemplar Next-Generation Immunohistochemical Marker: A Molecularly Informed, Pattern-Based Approach, Methodological Considerations, and Pan-Cancer Diagnostic Applications
Bellizzi, A. M. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001144 · Cited by 24
T cell receptors employ diverse strategies to target a p53 cancer neoantigen
Wu, D., Gowathaman, R., Pierce, B. G., & Mariuzza, R. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101684 · Cited by 26
Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations
Wang, F., Zhang, H., Wang, H., Qiu, T., He, B., & Yang, Q. (2022) · Medical Oncology · doi:10.1007/s12032-022-01777-x · Cited by 23
Anticancer Therapeutic Strategies Targeting p53 Aggregation
Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911023 · Cited by 23
A Water‐Stable and Red‐Emissive Radical Cation for Mutp53 Cancer Therapy
Zhou, Z., Qian, J., Liu, K., Zhang, Y., Gao, M., & Tang, B. Z. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202212671 · Cited by 23
The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis
Zhang, R., Tian, P., Chen, B., Wang, T., & Li, W. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1585690 · Cited by 23
Targeting TP53 Mutations in Myelodysplastic Syndromes
Hunter, A. M., & Sallman, D. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.004 · Cited by 25
High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer –Results from a prospective pilot study using a 37 gene panel
Nientiedt, C., Endris, V., Jenzer, M., Mansour, J., Sedehi, N. T. P., Pecqueux, C., Volckmar, A., Leichsenring, J., Neumann, O., Kirchner, M., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.03.001 · Cited by 25
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment
Bhatta, B., Luz, I., Krueger, C., Teo, F. X., Lane, D. P., Sabapathy, K., & Cooks, T. (2021) · Cancers · doi:10.3390/cancers13122985 · Cited by 24
Self-citation
Advancements in p53-Based Anti-Tumor Gene Therapy Research
Peng, Y., Bai, J., Wang, L., Su, Z., & Cheng, X. (2024) · Molecules · doi:10.3390/molecules29225315 · Cited by 20
miR-552 promotes laryngocarcinoma cells proliferation and metastasis by targeting p53 pathway
Gu, J., Han, T., Sun, L., Yan, A., & Jiang, X. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1743910 · Cited by 21
Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
Curylova, L., Ramos, H., Saraiva, L., & Skoda, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.037 · Cited by 21
Partial p53 reactivation is sufficient to induce cancer regression
Klimovich, B., Meyer, L., Merle, N., Neumann, M. M., König, A. M., Ananikidis, N., Keber, C. U., Elmshäuser, S., Timofeev, O. N., & Stiewe, T. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02269-6 · Cited by 22
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities
Ho, T. L. F., Lee, M. Y., Goh, H. C., Ng, G. Y. N., Lee, J. J. H., Kannan, S., Lim, Y. T., Zhao, T., Lim, E. K. H., Phua, C. Z. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37223-3 · Cited by 21
Self-citation
Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis
Pavlakis, E., Neumann, M. M., Merle, N., Wieboldt, R., Wanzel, M., Ponath, V., von Strandmann, E. P., Elmshäuser, S., & Stiewe, T. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02785-z · Cited by 21
Characterization of the generic mutant p53-rescue compounds in a broad range of assays
Xiao, S., Shi, F., Song, H., Cui, J., Zheng, D., Zhang, H., Tan, K. W., Wu, J., Chen, X., Wu, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.008 · Cited by 21
Loss of p53 epigenetically modulates epithelial to mesenchymal transition in colorectal cancer
Sharma, S., Rani, H., Mahesh, Y., Jolly, M. K., Dixit, J., & Mahadevan, V. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101848 · Cited by 21
SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations
Gomes, A. S., Ramos, H., Gomes, S., Loureiro, J. B., Soares, J., Barcherini, V., Monti, P., Fronza, G., Oliveira, C., Domingues, L., et al. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.129440 · Cited by 21
Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
Kobayashi, K., & Tan, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044126 · Cited by 22
Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant
Li, W., Li, L., Yang, H., Shi, C., Lei, Z., Guo, L., & Wang, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2907272 · Cited by 20
Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density
Calvocoressi, L., Uchio, E., Ko, J., Radhakrishnan, K., Aslan, M., & Concato, J. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000804 · Cited by 20
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
Bories, P., Prade, N., Lagarde, S., Cabarrou, B., Largeaud, L., Plenecassagnes, J., Luquet, I., Mas, V. M., Filleron, T., Cassou, M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238795 · Cited by 20
Zinc-doped Prussian blue nanoparticles for mutp53-carrying tumor ion interference and photothermal therapy
Jin, Q., Zuo, W., Lin, Q., Wu, T., Liu, C., Liu, N., Liu, J., & Zhu, X. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.07.003 · Cited by 20
TP53 in AML and MDS: The new (old) kid on the block
Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 20
Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines
Huber, A., Allam, A. H., Dijkstra, C., Thiem, S., Huynh, J., Poh, A. R., Konecnik, J., Jacob, S. P., Busuttil, R. A., Liao, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114616 · Cited by 20
Mutant p53 Gain of Function: Why Many See It, Why Some Do Not
Lozano, G., Prives, C. L., & Sabapathy, K. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1638 · Cited by 24
Self-citation
Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth
Wang, J., Chen, Y., Huang, C., Hao, Q., Zeng, S. X., Omari, S., Zhang, Y., Zhou, X. Y., & Lu, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3855 · Cited by 19
Therapeutic targets in cancer treatment: Cell cycle proteins
Selvaraj, C. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.003 · Cited by 19
p53 Function and Dysfunction in Human Health and Diseases
D’Orazi, G. (2023) · Biomolecules · doi:10.3390/biom13030506 · Cited by 19
Emerging insights into ethnic-specific TP53 germline variants
Fischer, N. W., Ma, Y.-H. V., & Gariépy, J. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad106 · Cited by 24
TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches
Pereira, M. P., Herrity, E., & Kim, D. D. H. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05462-5 · Cited by 20
Cytogenetics and genomics of acute myeloid leukemia
Snaith, O., Poveda-Rogers, C., Laczko, D. I., Yang, G., & Morrissette, J. J. D. (2023) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2023.101533 · Cited by 23
How MicroRNAs Command the Battle against Cancer
Wu, H. H., Leng, S., Sergi, C. M., & Leng, R. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115865 · Cited by 22
Detecting PI3K and TP53 Pathway Disruptions in Early‐Onset Colorectal Cancer Among Hispanic/Latino Patients
Monge, C., Waldrup, B., Manjarrez, S., Carranza, F., & Velazquez-Villarreal, E. I. (2025) · Cancer Medicine · doi:10.1002/cam4.70791 · Cited by 18
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma
Murnyák, B., & Huang, L. E. (2021) · Cells · doi:10.3390/cells10082116 · Cited by 18

Authors: Sabapathy, K., & Lane, D. P.
Affiliations: National University of Singapore (SG)
Agency for Science, Technology and Research (SG)
Corresponding author: Sabapathy, Kanaga
Lane, David P.
ORCID: Sabapathy, Kanaga
Lane, David P.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-09-26
Volume: 15
Issue: 1
Pages: 13-30
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.151
OpenAlex: W2759444489
Cited by: 517
References: 178
Citations by year: 2026: 40 · 2025: 67 · 2024: 74 · 2023: 89 · 2022: 57 · 2021: 64 · 2020: 53 · 2019: 41 · 2018: 26 · 2017: 3
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Research Foundation Singapore
National Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: TP53 mutation, mutant p53, p53-targeted therapy, tumour suppressor, cancer therapy resistance, prognostic factors
MeSH terms: Humans, Mutation, Neoplasms, Genes, p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks